Impact of Alcohol Misuse on Cognitive and Respiratory Outcomes in COVID-19-associated Acute Respiratory Failure

滥用酒精对 COVID-19 相关急性呼吸衰竭患者认知和呼吸结果的影响

基本信息

  • 批准号:
    10391807
  • 负责人:
  • 金额:
    $ 21.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-22 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract During the Coronavirus (COVID)-19 pandemic, the number of patients diagnosed with the acute respiratory distress syndrome (ARDS) has increased dramatically in the US. COVID-19-associated ARDS is characterized by high morbidity, including a requirement for protracted mechanical ventilator support. In a substantial percentage of patients who survive hospitalization, deficits including neurocognitive dysfunction and residual pulmonary impairment have been reported as so-called Post-Acute Sequelae of COVID-19 (PASC). Therefore, it is imperative to urgently establish addressable factors that drive poor outcomes. Prior to the COVID-19 pandemic, investigations by our research group demonstrated that alcohol misuse is associated with an increased severity of ARDS, which may contribute to residual pulmonary dysfunction in survivors. Alcohol misuse can also propagate development of delirium that may increase risk for cognitive impairment in recovery. Notably, delirium has been reported in half of all COVID-19 patients in the ICU, and alcohol misuse appears to increase odds for its development. Although reports of increasing alcohol misuse during the pandemic are widespread and might be one modifiable factor driving severity of illness and outcomes, its impact on the trajectory of illness in COVID-19 has not been fully evaluated. The goal of this proposal is to determine if alcohol misuse promotes ICU delirium that in turn increases requirements for mechanical ventilation among patients with COVID-19-associated ARDS. Also, we wish to establish if alcohol misuse contributes to persistent cognitive and respiratory PASC in COVID-19 survivors. To address these questions, two aims are proposed. Aim 1: In hospitalized patients with COVID-19-associated ARDS, determine if alcohol misuse is associated with increased mechanical ventilation requirements, and if delirium further influences this relationship. Investigations will be conducted in a prospectively enrolled cohort of patients with COVID-19- associated ARDS, who are in the ICU at the University of Colorado Hospital (Aim 1a), and in a retrospective cohort of hospitalized patients with COVID-19, previously admitted in the University of Colorado Health system (Aim 1b). Aim 2: Among patients recovering from COVID-19, determine the impact of alcohol misuse on cognition and respiratory function in recovery, accounting for characteristics of acute illness that include requirements for mechanical ventilation and ICU delirium. Investigations will be conducted in patients followed in a multidisciplinary COVID-19 Recovery Clinic, who will have cognitive, mental, and respiratory health evaluated over the year following hospital discharge. Our proposed research will help determine if patients with alcohol misuse warrant targeted strategies to identify and treat delirium in the setting of COVID-19-associated respiratory failure, and it will clarify if hospitalized patients with COVID-19 and alcohol misuse represent a unique subgroup at risk for PASC who may merit specific services or interventions.
项目概要/摘要 在冠状病毒 (COVID)-19 大流行期间,诊断出患有急性呼吸道疾病的患者人数 窘迫综合症(ARDS)在美国急剧增加。 COVID-19 相关 ARDS 的特征 发病率高,包括需要长期机械呼吸机支持。在实质性的 住院患者存活率、神经认知功能障碍和残留缺陷等缺陷 据报道,肺损伤被称为所谓的 COVID-19 急性后遗症 (PASC)。所以, 迫切需要找出导致不良结果的可解决因素。在 COVID-19 之前 大流行期间,我们研究小组的调查表明,滥用酒精与 ARDS 严重程度增加,可能导致幸存者残留肺功能障碍。酒精 误用还会导致谵妄的发生,从而增加认知障碍的风险 恢复。值得注意的是,ICU 中一半的 COVID-19 患者报告出现谵妄,并且酗酒 似乎增加了其发展的可能性。尽管有报道称,疫情期间酗酒现象有所增加 大流行病很普遍,可能是导致疾病严重程度和结果的一个可改变的因素,其 对 COVID-19 疾病轨迹的影响尚未得到充分评估。该提案的目标是 确定酒精滥用是否会导致 ICU 谵妄,进而增加对机械的要求 COVID-19 相关 ARDS 患者的通气。此外,我们希望确定是否滥用酒精 有助于 COVID-19 幸存者的持续认知和呼吸 PASC。为了解决这些问题, 提出了两个目标。目标 1:在患有 COVID-19 相关 ARDS 的住院患者中,确定是否饮酒 误用与机械通气需求增加有关,如果谵妄进一步影响这一点 关系。调查将在前瞻性招募的 COVID-19 患者队列中进行 相关的 ARDS,他们在科罗拉多大学医院的 ICU 中(目标 1a),并且在一项回顾性研究中 科罗拉多大学卫生系统先前收治的 COVID-19 住院患者队列 (目标 1b)。目标 2:在从 COVID-19 中康复的患者中,确定滥用酒精对健康的影响 恢复中的认知和呼吸功能,考虑到急性疾病的特征,包括 机械通气和 ICU 谵妄的要求。将对患者进行调查 在多学科 COVID-19 康复诊所中,患者将获得认知、心理和呼吸系统健康 出院后一年内进行评估。我们提出的研究将有助于确定患者是否患有 酒精滥用需要采取有针对性的策略来识别和治疗与 COVID-19 相关的谵妄 呼吸衰竭,它将澄清住院的 COVID-19 患者和酗酒患者是否代表了呼吸衰竭 面临 PASC 风险的独特亚群,可能需要特定的服务或干预措施。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ELLEN L BURNHAM其他文献

ELLEN L BURNHAM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ELLEN L BURNHAM', 18)}}的其他基金

Impact of Dual Alcohol and Cannabis Use on Lung
双重酒精和大麻使用对肺的影响
  • 批准号:
    10302164
  • 财政年份:
    2021
  • 资助金额:
    $ 21.7万
  • 项目类别:
Impact of Alcohol Misuse on Cognitive and Respiratory Outcomes in COVID-19-associated Acute Respiratory Failure
滥用酒精对 COVID-19 相关急性呼吸衰竭患者认知和呼吸结果的影响
  • 批准号:
    10491334
  • 财政年份:
    2021
  • 资助金额:
    $ 21.7万
  • 项目类别:
Impact of Dual Alcohol and Cannabis Use on Lung
双重酒精和大麻使用对肺的影响
  • 批准号:
    10471332
  • 财政年份:
    2021
  • 资助金额:
    $ 21.7万
  • 项目类别:
Impact of Alcohol Misuse on Cognitive and Respiratory Outcomes in COVID-19-associated Acute Respiratory Failure
滥用酒精对 COVID-19 相关急性呼吸衰竭患者认知和呼吸结果的影响
  • 批准号:
    10671588
  • 财政年份:
    2021
  • 资助金额:
    $ 21.7万
  • 项目类别:
Institutional Career Development Core
机构职业发展核心
  • 批准号:
    9623478
  • 财政年份:
    2018
  • 资助金额:
    $ 21.7万
  • 项目类别:
Institutional Career Development Core
机构职业发展核心
  • 批准号:
    9927714
  • 财政年份:
    2018
  • 资助金额:
    $ 21.7万
  • 项目类别:
Institutional Career Development Core
机构职业发展核心
  • 批准号:
    10406153
  • 财政年份:
    2018
  • 资助金额:
    $ 21.7万
  • 项目类别:
Celiac disease signatures in Down syndrome (KL2 Admin Suppl)
唐氏综合症的乳糜泻特征(KL2 Admin Suppl)
  • 批准号:
    10117961
  • 财政年份:
    2018
  • 资助金额:
    $ 21.7万
  • 项目类别:
Clinical Resource for Lung and Alcohol Investigations
肺和酒精研究的临床资源
  • 批准号:
    8308358
  • 财政年份:
    2011
  • 资助金额:
    $ 21.7万
  • 项目类别:
CoPARC: Colorado Pulmonary Alcohol Research Collaborative
CoPARC:科罗拉多州肺酒精研究合作组织
  • 批准号:
    9926794
  • 财政年份:
    2011
  • 资助金额:
    $ 21.7万
  • 项目类别:

相似国自然基金

剪接因子U2AF1突变在急性髓系白血病原发耐药中的机制研究
  • 批准号:
    82370157
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
IKZF1-N159Y/S热点突变在急性白血病中的致病机制研究
  • 批准号:
    82300168
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
NMNAT1上调B7-H3介导急性早幼粒细胞白血病免疫逃逸的作用和机制研究
  • 批准号:
    82300169
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
支链氨基酸转氨酶1在核心结合因子急性髓细胞白血病中的异常激活与促进白血病发生的分子机制研究
  • 批准号:
    82370178
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
SRSF3/LRP5/Wnt信号通路在急性淋巴细胞白血病中的作用及机制研究
  • 批准号:
    82370128
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

Development of a Neutrophil Degranulation Inhibitor to Treat ARDS
开发治疗 ARDS 的中性粒细胞脱颗粒抑制剂
  • 批准号:
    10697442
  • 财政年份:
    2023
  • 资助金额:
    $ 21.7万
  • 项目类别:
Identifying patient subgroups and processes of care that cause outcome differences following ICU vs. ward triage among patients with acute respiratory failure and sepsis
确定急性呼吸衰竭和脓毒症患者在 ICU 与病房分诊后导致结局差异的患者亚组和护理流程
  • 批准号:
    10734357
  • 财政年份:
    2023
  • 资助金额:
    $ 21.7万
  • 项目类别:
Development of a Neutrophil Degranulation Inhibitor to Treat ARDS
开发治疗 ARDS 的中性粒细胞脱颗粒抑制剂
  • 批准号:
    10697442
  • 财政年份:
    2023
  • 资助金额:
    $ 21.7万
  • 项目类别:
Restoring immune-vascular axis integrity to alleviate acute lung injury in sepsis
恢复免疫血管轴完整性以减轻脓毒症急性肺损伤
  • 批准号:
    10683797
  • 财政年份:
    2022
  • 资助金额:
    $ 21.7万
  • 项目类别:
Microbial Determinants of Acute Respiratory Distress Syndrome Severity (MiDAS)
急性呼吸窘迫综合征严重程度的微生物决定因素 (MiDAS)
  • 批准号:
    10417975
  • 财政年份:
    2022
  • 资助金额:
    $ 21.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了